Efficacy And Safety Of Radiosensitizer Metronidazole Amino Acidum Natrium (CMNa) For Patients With Non-small Cell Lung Cancer:a Meta-analysis

Objective:This meta-analysis aimed to investigate the influence of metronidazole amino acidum natrium (CMNa) on the efficacy and safety of three dimensional conformal radiotherapy (3D-CRT) for patients with non-small cell lung cancer (NSCLC).Methods:Data collection of relevant clinical controlled trials were extensively selected from both Chinese and English databases. Meta-analysis was conducted by ReviewManager5.0software. The odds ratio (OR) with95%confidence intervals (CI) were calculated.Results:According to inclusion criteria,11random clinical trials (RCTs) were assessed with a total of759NSCLC patients, including400patients in the CMNa group and359patients in the control group. Meta-analysis showed that CMNa may improve clinical efficacy rate (OR=3.24,95%CI [2.32,4.53], P<0.001),1-year survival rate (OR=1.48,95%CI [1.02,2.14], P=0.04) and2-year survival rate (OR=1.82,95%CI[1.12,2.97], P=0.02) for NSCLC patients who received3D-CRT radiotherapy. Furthermore, the rate of radioactive esophageal injury (OR=0.67,95%CI [0.46,0.98], P=0.04), lung injury (OR=0.51,95%CI [0.31,0.83], P=0.008) and myelosuppression (OR=0.51,95%CI [0.32,0.81], P=0.004) in the control group were higher than in the CMNa group.Conclusion:The present meta-analysis indicates that CMNa may improve clinical efficacy rate,1-year and2-year survival rate, and reduce the the rate of adverse effects for NSCLC patients who received3D-CRT radiotherapy.